Income statement
USD
Annual
| Metric | 2025 | 2024 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 134K | 3K | 104K | 1M | 1M |
| Gross Profit | 8K | -209K | 53K | 821K | 1M |
| Operating Income | -1M | -2M | -1M | -2M | -712K |
| EBITDA | -1M | -2M | -1M | -2M | -699K |
| Net Income | -1M | -2M | -1M | -2M | -712K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.007
+0.00% today
1Y Change
-90.27%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Yubo International Biotech Limited (YBGJ) is a Healthcare stock with listed on OTC. The stock last traded around $0.01 and down 90.3% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +3772.9%, EPS growth of +32.4%, a dividend yield of 0.0%. What stands out right now is revenue +3772.9%, EPS +32.4%, free cash flow +37.0% with operating margin -883.8% and ROIC 57.8%. Valuation sits in the middle of the pack at price/sales 7.5. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines YBGJ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
YBGJ
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
YBGJ Max Drawdown
-94.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for YBGJ and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.4M
+8.8% YoY
FY Net Income
-$711.8K
+53.8% YoY
Free Cash Flow
$3.6K
+100.2% YoY
Revenue Growth
+3772.9%
EPS Growth
+32.4%
Gross Margin
6.1%
Net Margin
-803.1%
Income statement
USD
| Metric | 2025 | 2024 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 134K | 3K | 104K | 1M | 1M |
| Gross Profit | 8K | -209K | 53K | 821K | 1M |
| Operating Income | -1M | -2M | -1M | -2M | -712K |
| EBITDA | -1M | -2M | -1M | -2M | -699K |
| Net Income | -1M | -2M | -1M | -2M | -712K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 8K | 7K | 18K | 28K | 1M |
| Total Assets | 847K | 2M | 2M | 5M | 2M |
| Total Liabilities | 3M | 5M | 3M | 5M | 1M |
| Shareholder Equity | -2M | -3M | -565K | -131K | 1M |
| Total Debt | 79K | 479K | 790K | 3M | 315K |
| Net Debt | 71K | 472K | 772K | 3M | -1M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
101K
+109.9% YoY
Capital Expenditures
97K
+82.7% YoY
Free Cash Flow
4K
+100.2% YoY
Key ratios
Gross Margin
6.1%
Operating Margin
-883.8%
Net Margin
-803.1%
ROE
38.2%
Debt / Equity
-0.04x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.